CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: May 6, 2008
Result type: Reports
Project Number: SR0133-000
Product Line: Reimbursement Review

Generic Name: Natalizumab

Brand Name: Tysabri

Manufacturer: Biogen Idec Canada Inc.

Therapeutic Area: Multiple Sclerosis, relapsing-remitting

Indications: Multiple Sclerosis, relapsing-remitting

Submission Type: Resubmission

Project Status: Complete

Date Recommendation Issued: February 25, 2009

Recommendation Type: List with clinical criteria and/or conditions